Ernexa Therapeutics (ERNAW) Long-Term Investments (2021 - 2023)

Ernexa Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $8000.0 in Q1 2023.

• For the quarter ending Q1 2023, Long-Term Investments fell 97.92% year-over-year to $8000.0; the trailing twelve-month figure through Mar 2023 stood at $8000.0 (down 97.92% YoY), and the FY2022 full-year result was $59000.0, down 94.1% from the prior year.
• Long-Term Investments for Q1 2023 stood at $8000.0, down from $59000.0 in the prior quarter.
• The five-year high for Long-Term Investments was $1.0 million in Q3 2021, with the low at $8000.0 in Q1 2023.
• Historically, Long-Term Investments has averaged $372714.3 across 3 years, with a median of $89000.0 in 2022.
• Annual changes were most pronounced in 2022 — Long-Term Investments sank 93.2% — and 2023, when it tumbled 97.92%.
• Ernexa Therapeutics' Long-Term Investments stood at $1.0 million in 2021, then plunged by 94.1% to $59000.0 in 2022, then slumped by 86.44% to $8000.0 in 2023.
• The last three Long-Term Investments figures came in at $8000.0 (Q1 2023), $59000.0 (Q4 2022), and $68000.0 (Q3 2022), per Business Quant data.